US · STAA
STAAR Surgical Company
- Sector
- Healthcare · Medical - Instruments & Supplies
- Headquarters
- Lake Forest, CA 92630
- Website
- staar.com
Price · as of 2024-12-27
$27.19
Market cap 982.38M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $38.12 | +40.2% |
| Intrinsic Value(DCF) | $8.15 | -70.03% |
| Graham-Dodd Method(GD) | $6.00 | -77.95% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2010 | $0.00 | $0.00 | |||
| 2011 | $0.97 | $0.83 | |||
| 2012 | $0.60 | $0.00 | |||
| 2013 | |||||
| 2014 | $1.06 | $0.23 | |||
| 2015 | $0.00 | $0.00 | |||
| 2016 | $0.11 | $0.00 | |||
| 2017 | $0.74 | $0.00 | |||
| 2018 | $3.44 | $4.77 | |||
| 2019 | |||||
| 2020 | $5.13 | $8.97 | |||
| 2021 | $4.93 | $2.15 | |||
| 2022 | $56.63 | $63.35 | $129.98 | $11.10 | $25.22 |
| 2023 | $35.86 | $59.83 | $85.58 | $10.12 | $9.22 |
| 2024 | $18.34 | $38.12 | $1.25 | $6.00 | $0.00 |
AI valuation
Our deep-learning model estimates STAAR Surgical Company's (STAA) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $38.12
- Current price
- $27.19
- AI upside
- +40.2%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$8.15
-70.03% upside
Graham-Dodd
$6.00
-77.95% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| STAA | STAAR Surgical Company | $27.19 | 982.38M | +40% | -70% | -78% | — | -44.58 | 2.27 | 2.87 | -123.99 | — | 2.28 | 76.32% | -4.02% | -6.44% | -5.16% | -6.20% | -4.05% | 0.10 | — | 5.23 | 4.41 | 18.43 | -19535.00% | -264.00% | 11338.00% | -0.85% | 0.22 | -3.77% | 0.00% | 0.00% | 0.17% | -56.24 | -92.48 | 2.26 | 5.87 |
| AZTA | Azenta, Inc. | $26.98 | 1.24B | +62% | -42% | -40% | — | -28.75 | 0.93 | 2.70 | 25.40 | — | 1.74 | 45.52% | -1.90% | -9.39% | -3.19% | -0.31% | -2.68% | 0.06 | — | 2.98 | 2.23 | -3.12 | -6052.00% | 355.00% | 21029.00% | 2.39% | 0.30 | 2.67% | 0.00% | 0.00% | 0.00% | -121.90 | 35.84 | 2.31 | 4.42 |
| BBNX | Beta Bionics, Inc. | $12.63 | 560.55M | +248% | +7,672% | — | — | -6.93 | 1.76 | 5.06 | -4.11 | — | 1.76 | 55.40% | -71.50% | -73.02% | -40.26% | -236.00% | -30.60% | 0.04 | — | 8.66 | 7.64 | 0.26 | -7895.00% | 5394.00% | -10000.00% | 0.00% | 0.00 | 0.00% | 0.00% | 0.00% | 0.00% | -4.20 | — | 3.00 | 6.28 |
| BLFS | BioLife Solutions, Inc. | $24.20 | 1.17B | +49% | -55% | -73% | — | — | 2.89 | 11.18 | -103.07 | — | 2.89 | 64.56% | -12.61% | -12.61% | 0.00% | -4.52% | 0.00% | 0.03 | -4.48 | 5.23 | 5.23 | -1.18 | -4318.00% | 1697.00% | 28653.00% | 1.87% | 0.88 | 7.49% | 0.00% | — | 0.00% | -79.66 | 48.04 | 10.04 | 18.23 |
| KMTS | KESTRA MEDICAL TECHNOLOGI… | $23.28 | 1.36B | +67% | +283% | — | — | -6.49 | 3.60 | 12.35 | -5.57 | -4.28 | 3.60 | 40.47% | -177.85% | -190.28% | 5732.26% | 132.69% | -66.62% | 0.22 | -13.75 | 6.72 | 6.47 | 1.97 | 15147.00% | 11505.00% | 1941.00% | -13.70% | -2.04 | 126.23% | 0.22% | -1.50% | 31.39% | -5.13 | -5.39 | 9.12 | 2.34 |
| NVCR | NovoCure Limited | $13.67 | 1.53B | +107% | -55% | — | — | -11.06 | 4.43 | 2.30 | -11.25 | — | 4.43 | 74.54% | -23.47% | -20.79% | -38.89% | -119.85% | -13.32% | 0.85 | — | 2.90 | 2.57 | -1.57 | -2179.00% | 828.00% | 932.00% | -5.02% | -0.22 | -58.98% | 0.00% | 0.00% | 22.09% | -8.71 | -17.70 | 2.04 | 0.52 |
| ORIC | ORIC Pharmaceuticals, Inc… | $13.45 | 1.31B | — | — | — | — | -9.41 | 3.17 | — | -7.40 | — | 3.17 | 0.00% | — | — | -41.27% | -272.98% | -37.79% | 0.03 | — | 14.13 | 13.79 | 0.27 | -1967.00% | — | 20.00% | -9.36% | -5.55 | -217.77% | 0.00% | 0.00% | 0.00% | -6.63 | -8.32 | — | 24.72 |
| PGEN | Precigen, Inc. | $3.79 | 1.14B | +633% | -73% | — | +239% | -3.94 | 12.93 | 126.87 | -3.28 | -19.23 | 33.38 | -8.71% | -3440.23% | -3216.18% | -160.80% | -3010.47% | -85.20% | 0.14 | -22504.83 | 4.76 | 4.60 | 0.19 | 2051.00% | -3695.00% | 1211.00% | -15.41% | -3.17 | -1735.60% | 0.00% | 0.00% | 4.73% | -3.00 | -5.28 | 103.33 | -19.72 |
| PLSE | Pulse Biosciences, Inc. | $18.73 | 1.27B | — | — | — | — | -17.46 | 15.75 | 3629.72 | -16.69 | -100.37 | 16.44 | -360.00% | -21982.57% | -20794.57% | -74.45% | -1168.13% | -63.68% | 0.09 | — | 10.53 | 10.22 | 1.02 | 1739.00% | — | 4927.00% | -4.29% | -6.83 | -826.49% | 0.00% | 0.00% | 0.00% | -15.56 | -21.99 | 3420.56 | 40.87 |
| TERN | Terns Pharmaceuticals, In… | $42.12 | 3.79B | — | — | — | — | -3.12 | 0.80 | — | 0.79 | — | 0.80 | 0.00% | — | — | -29.56% | 1106.27% | -28.10% | 0.00 | — | 23.14 | 22.89 | 1.59 | -1181.00% | — | 388.00% | -25.25% | -4.47 | 760.80% | 0.00% | 0.00% | 29.11% | 0.78 | 1.13 | — | 7.82 |
About STAAR Surgical Company
STAAR Surgical Company, together with its subsidiaries, designs, develops, manufactures, markets, and sells implantable lenses for the eye, and companion delivery systems to deliver the lenses into the eye. The company provides Visian implantable Collamer lens product family (ICLs) to treat visual disorders, such as myopia, hyperopia, astigmatism, and presbyopia; and Hyperopic ICL, which treats far-sightedness. It also offers preloaded silicone cataract intraocular lenses and injector systems for use in cataract surgery. In addition, the company sells injector parts, and other related instruments and devices. It markets its products to health care providers, including ophthalmic surgeons, vision and surgical centers, hospitals, government facilities, and distributors, as well as products are primarily used by ophthalmologists. The company sells its products directly through its sales representatives in the United States, Japan, Germany, Spain, Canada, the United Kingdom, and Singapore, as well as through own representatives and independent distributors in China, Korea, India, France, Benelux, Italy, and internationally. STAAR Surgical Company was incorporated in 1982 and is headquartered in Lake Forest, California.
- CEO
- Warren Foust
- Employees
- 1.16K
- Beta
- 1.07
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($8.15 ÷ $27.19) − 1 = -70.03% (DCF, example).